This is a fascinating article full of technical detail about an emerging alternative thesis explaining the progression from NAFLD to NASH. It also goes into detail about how biopharma company Gilead is pursuing multiple avenues and theories on NASH progression as part of a comprehensive plan to create a medical treatment for it. Continue reading “Lipotoxicity and NASH”